Pim Mutsaers

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar, Scott R. Solomon, Jon Arnason et al. · The Lancet · 2022 · 752 citations

Medicine, Oncology, Chemotherapy +13

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason et al. · Blood · 2022 · 368 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group

Anne M. Spanjaart, Per Ljungman, Rafael de la Cámara et al. · Leukemia · 2021 · 116 citations · Full text

Medicine, Hematology, Infectious Diseases +16

Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study

Manali Kamdar, Scott R. Solomon, Jon Arnason et al. · Blood · 2021 · 88 citations

Medicine, Immunology, Oncology +17

Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19

Sabine Haggenburg, Quincy Hofsink, Birgit I. Lissenberg‐Witte et al. · JAMA Oncology · 2022 · 85 citations · Full text

Medicine, Immunology, Oncology +17